Recent Updates
Recently added Catalysts

Ulcerative Colitis: 6 biotech companies competing in the clinic

Immunology & InflammationGold rushData as of 2026-09-04

Competitors6in the clinic
Median market cap$1.8Buniverse median $1.20B
Allocated capital$8.5B$22.9B competing
Phase 3 or filed23 mid, 1 early
Pure plays1this indication only
Capital rank19/299crowding rank 24

Ulcerative Colitis is both crowded and richly priced: 6 companies are in the clinic and the median one is worth $1.8B, against a universe median of $1.20B.

Crowded fields usually trade at a discount per company, so a premium in a field this deep says the market is pricing the size of the prize above the cost of the competition.

2 of the 6 are in Phase 3 or filed, and 6 dated catalysts fall in the next 12 months, so this ranking is likely to move.

$8.5B of allocated capital sits in Ulcerative Colitis, 19th of 299 indications, and 1 of the 6 companies are pure plays that trade on this indication alone.

Companies developing drugs for Ulcerative Colitis 6

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ABVXAbivaxABX464Phase 32$9.9BNo3 31 Dec 2026
VNDAVanda PharmaceuticalsPonesimodPhase 31$323MNo7 12 Dec 2026
SYRESpyre TherapeuticsSPY001Phase 26$7.7BNo3 30 Sep 2026
ANABAnaptysBioRosnilimabPhase 21$1.7BNo2 12 Dec 2026
ODTXOdyssey TherapeuticsOD-07656Phase 22$1.3BYes1 31 Dec 2026
XNCRXencorXmAb942Phase 11$2.0BNo4 23 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. ABVX holds 44% of the $22.9B competing in this indication.

Why Ulcerative Colitis is a gold rush

Crowded and richly priced: six or more competitors, and the median one is worth more than the median small or mid cap biotech.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Ulcerative Colitis has 6 competitors and a median of $1.8B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Rheumatoid Arthritis9 companies · $8.6B · median $1.7BGold rushGeneralized Myasthenia Gravis8 companies · $8.9B · median $1.8BGold rushHidradenitis Suppurativa4 companies · $9.5B · median $3.7BConcentrated betSystemic Lupus Erythematosus13 companies · $7.2B · median $1.2BKnife fightIdiopathic Pulmonary Fibrosis7 companies · $5.8B · median $1.3BGold rushAndrogenetic Alopecia2 companies · $5.6B · median $2.8BConcentrated betCrohn's Disease4 companies · $5.1B · median $714MOrphan cornerAsthma6 companies · $12.1B · median $5.2BGold rush

Ulcerative Colitis pipeline questions

Which biotech companies are developing drugs for Ulcerative Colitis?

6 US-listed companies in the $100M to $20B market cap band run clinical programmes in Ulcerative Colitis. The largest and most advanced are Abivax (ABVX, ABX464, Phase 3); Vanda Pharmaceuticals (VNDA, Ponesimod, Phase 3); Spyre Therapeutics (SYRE, SPY001, Phase 2); AnaptysBio (ANAB, Rosnilimab, Phase 2); Odyssey Therapeutics (ODTX, OD-07656, Phase 2). The full list of 6 is in the table on this page.

How advanced is the Ulcerative Colitis pipeline?

Of the 6 clinical-stage programmes in Ulcerative Colitis, 2 are in Phase 3 or filed, 3 are in mid-stage development and 1 is in early-stage development.

How much is the typical Ulcerative Colitis biotech company worth?

The median company developing a drug for Ulcerative Colitis is worth $1.8B, against a median of $1.20B across the whole universe. $8.5B of allocated capital sits in the indication, ranking it 19th of 299.

When is the next Ulcerative Colitis catalyst?

The next dated catalyst in Ulcerative Colitis is SYRE on 30 Sep 2026. 6 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map